Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.92 USD
Change Today -0.31 / -5.93%
Volume 664.7K
CPRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

catalyst pharmaceuticals inc (CPRX) Snapshot

Open
$5.21
Previous Close
$5.23
Day High
$5.28
Day Low
$4.86
52 Week High
07/21/15 - $5.80
52 Week Low
08/8/14 - $2.15
Market Cap
403.5M
Average Volume 10 Days
964.5K
EPS TTM
$-0.24
Shares Outstanding
82.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CATALYST PHARMACEUTICALS INC (CPRX)

Related News

No related news articles were found.

catalyst pharmaceuticals inc (CPRX) Related Businessweek News

No Related Businessweek News Found

catalyst pharmaceuticals inc (CPRX) Details

Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders. The company offers Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. It is also involved in the development of CPP-115, a GABA aminotransferase inhibitor, which is in Phase Ib clinical trial for the treatment of epilepsy and other selected neurological indications, such as complex partial seizures and Tourette Syndrome; and CPP-109 for the treatment of Tourette Syndrome. Catalyst Pharmaceuticals, Inc. has a strategic collaboration agreement with BioMarin Pharmaceutical, Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

12 Employees
Last Reported Date: 03/13/15
Founded in 2002

catalyst pharmaceuticals inc (CPRX) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $510.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $288.0K
Chief Operating Officer and Chief Scientific ...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

catalyst pharmaceuticals inc (CPRX) Key Developments

Catalyst Pharmaceuticals Initiates Rolling NDA Submission for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome

Catalyst Pharmaceuticals, Inc. announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for Firdapse® for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse® has received Breakthrough Therapy Designation from the FDA for the treatment of LEMS, as well as orphan drug designations for LEMS and congenital myasthenic syndromes (CMS). The Breakthrough Therapy Designation is designed to convey all of the fast track program features, as well as more intensive FDA guidance on an efficient drug development program. The Fast Track Designation is designed to facilitate the development and expedite the review of drugs that treat serious, life-threatening conditions and that address unmet medical needs. The Fast Track process allows a company to submit individual modules of its NDA for review by the FDA as they are completed.

Catalyst Pharmaceuticals, Inc. Announces Executive Changes

Catalyst Pharmaceuticals, Inc. announced the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr. Ingenito will report to Dr. Steven Miller, Catalyst’s Chief Operating Officer and Chief Scientific Officer. Following Dr. Ingenito’s joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company. Prior to joining Catalyst, Dr. Ingenito spent more than 25 years in the field of pharmaceutical development; including drugs, biologics, and combination products.

Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 2000 Index

Catalyst Pharmaceuticals, Inc. will be added to Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPRX:US $4.92 USD -0.31

CPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPRX.
View Industry Companies
 

Industry Analysis

CPRX

Industry Average

Valuation CPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CATALYST PHARMACEUTICALS INC, please visit www.catalystpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.